ERA-EDTA abstracts are out. Interesting stuff!

In "FP294: INHIBITION OF BET PROTEINS WITH APABETALONE REDUCES MEDIATORS OF VASCULAR CALCIFICATION IN VITRO AND IN CKD PATIENTS" they used ChIP-Seq (Chromatin Immunoprecipitation with DNA sequencing) to assess where BRD4 is physically localized to on DNA/chromatin in both the basal and osteogenic/trans-differentiated states of human coronary vascular smooth muscle cells. They also assessed how apabetalone affected this BRD4 DNA landscape. This isn't the first appearance of BRD4 ChIP-Seq data in a Resverlogix abstract. Earlier this month, Resverlogix presented at Vascular Discovery about BRD4 and FXR.

In "SP436: DESIGN FEATURES OF THE BETONMACE CHRONIC KIDNEY DISEASE SUB-STUDY; EFFECTS OF THE SELECTIVE BET-INHIBITOR APABETALONE ON KIDNEY FUNCTION AND MACE IN POST-ACS PATIENTS WITH ESTIMATED GLOMERULAR FILTRATION RATE BELOW 60 AND DIABETES" there are some details of the CKD sub study of BETonMACE. One part of the abstract really stood out to me: "To date, BETonMACE has randomized 2,224 patients of which 11% have screening eGFR below 60. At completion patients will have been treated from 6 to approximately 36 months." Based on this statement, one is lead to believe that the max dosing with apabetalone is not 2 years but is 3 years. First patient dosing started November 2015, so based on this abstract statement these patients may not have ever stopped dosing at 24 months but will continue on drug until trial end. 

BearDownAZ